Suppr超能文献

潜在血浆蛋白生物标志物的绝对定量靶向监测:一项针对健康个体的初步研究。

Absolute Quantitative Targeted Monitoring of Potential Plasma Protein Biomarkers: A Pilot Study on Healthy Individuals.

作者信息

Kononikhin Alexey S, Starodubtseva Natalia L, Brzhozovskiy Alexander G, Tokareva Alisa O, Kashirina Daria N, Zakharova Natalia V, Bugrova Anna E, Indeykina Maria I, Pastushkova Liudmila Kh, Larina Irina M, Mitkevich Vladimir A, Makarov Alexander A, Nikolaev Evgeny N

机构信息

Project Center of Advanced Mass Spectrometry Technologies, 121205 Moscow, Russia.

Institute of Biomedical Problems, Russian Federation State Scientific Research Center, Russian Academy of Sciences, 123007 Moscow, Russia.

出版信息

Biomedicines. 2024 Oct 21;12(10):2403. doi: 10.3390/biomedicines12102403.

Abstract

BACKGROUND/OBJECTIVES: The development of blood tests for the early detection of individual predisposition to socially significant diseases remains a pressing issue.

METHODS

In this pilot study, multiple reaction monitoring mass spectrometry (MRM-MS) with a BAK-270 assay was applied for protein concentrations analysis in blood plasma from 21 healthy volunteers of the European cohort.

RESULTS

The levels of 138 plasma proteins were reliably and precisely quantified in no less than 50% of samples. The quantified proteins included 66 FDA-approved markers of cardiovascular diseases (CVD), and other potential biomarkers of pathologies such as cancer, diabetes mellitus, and Alzheimer's disease. The analysis of individual variations of the plasma proteins revealed significant differences between the male (11) and female (10) groups. In total, fifteen proteins had a significantly different concentration in plasma; this included four proteins that exhibited changes greater than ±1.5-fold, three proteins (RBP4, APCS, and TTR) with higher levels in males, and one (SHBG) elevated in females. The obtained results demonstrated considerable agreement with the data collected from 20 samples of a North American cohort, which were analyzed with the similar MRM assay. The most significant differences between the cohorts of the two continents were observed in the level of 42 plasma proteins (including 24 FDA markers), of which 17 proteins showed a ≥1.5-fold change, and included proteins increased in North Americans (APOB, CRTAC1, C1QB, C1QC, C9, CRP, HP, IGHG1, IGKV4-1, SERPING1, RBP4, and AZGP1), as well as those elevated in Europeans (APOF, CD5L, HBG2, SELPLG, and TNA).

CONCLUSIONS

The results suggest a different contribution of specific (patho)physiological pathways (e.g., immune system and blood coagulation) to the development of socially significant diseases in Europeans and North Americans, and they should be taken into account when refining diagnostic panels.

摘要

背景/目的:开发用于早期检测个体对具有社会意义疾病易感性的血液检测方法仍然是一个紧迫的问题。

方法

在这项初步研究中,采用带有BAK - 270检测法的多反应监测质谱(MRM - MS)对来自欧洲队列的21名健康志愿者的血浆中的蛋白质浓度进行分析。

结果

在不少于50%的样本中可靠且精确地定量了138种血浆蛋白的水平。定量的蛋白质包括66种经美国食品药品监督管理局(FDA)批准的心血管疾病(CVD)标志物,以及其他如癌症、糖尿病和阿尔茨海默病等病理状况的潜在生物标志物。对血浆蛋白个体差异的分析显示男性(11名)和女性(10名)组之间存在显著差异。总共有15种蛋白质在血浆中的浓度有显著差异;其中包括4种变化幅度大于±1.5倍的蛋白质,3种在男性中水平较高的蛋白质(视黄醇结合蛋白4、富含半胱氨酸酸性分泌蛋白和甲状腺素转运蛋白),以及1种在女性中升高的蛋白质(性激素结合球蛋白)。获得的结果与从北美队列的20个样本中收集的数据相当一致,这些样本采用了类似的MRM检测法进行分析。在两大洲队列之间观察到的最显著差异在于42种血浆蛋白的水平(包括24种FDA标志物),其中17种蛋白质显示出≥1.5倍的变化,包括在北美人群中升高的蛋白质(载脂蛋白B、富含半胱氨酸和组氨酸的钙结合蛋白1、补体C1q亚基B、补体C1q亚基C、补体C9、C反应蛋白、触珠蛋白、免疫球蛋白G1、免疫球蛋白κ链可变区4 - 1、丝氨酸蛋白酶抑制剂C1、视黄醇结合蛋白4和锌α2糖蛋白),以及在欧洲人群中升高的蛋白质(载脂蛋白F、CD5L、血红蛋白γ亚基G2、选择素样蛋白G和TNA)。

结论

结果表明特定的(病理)生理途径(如免疫系统和血液凝固)对欧洲人和北美人群中具有社会意义疾病的发生发展有不同的贡献,在完善诊断指标时应予以考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5920/11504031/2410bd56e199/biomedicines-12-02403-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验